The passing of SB 218 through the Kentucky legislature created a new subsection of KRS 260.850m to 260.289, in which the Industrial Hemp Advisory Board outlines the purpose of an industrial hemp research program, establish license provisions, and create new requirements and license application procedures. This state’s approach is for the potential medical and industrial applications.
On October 17th 2018, Canada introduced the Cannabis Act, or Bill C-45. Under this new legislation, both medical and recreational cannabis use is federally legal in Canada. There are minimal changes to the medical stream, as patients can continue to purchase directly from their licensed producers and have their medical cannabis mailed directly to their home, including regulated & tested CBD oil.
As mentioned above, CBD is no longer considered a Schedule I controlled substance under the Farm Act. However, under the DEA’s definition, it remains on the list. This allows for individual states to create exceptions to the status of CBD, even when cultivated from hemp plants grown legally under the act. It also maintains illegal status for any CBD sourced from plants produced in settings that are not consistent with that Act, or by an unlicensed grower. It is expected that more clarification on the status of CBD will come early this year (2019).